BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20830690)

  • 41. The value of immunohistochemical expression of TTF-1, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas.
    Al-Zahrani IH
    Saudi Med J; 2008 Jul; 29(7):957-61. PubMed ID: 18626520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis.
    Irving JA; Young RH
    Am J Surg Pathol; 2005 Aug; 29(8):997-1006. PubMed ID: 16006793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unusual expression of thyroid transcription factor 1 and napsin A in metastatic adenoid cystic carcinoma of extrapulmonary origin in the lung.
    An J; Park S; Sung SH; Cho MS; Kim SC
    Am J Clin Pathol; 2014 May; 141(5):712-7. PubMed ID: 24713744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thyroid transcription factor-1 staining is useful in identifying brain metastases of pulmonary origin.
    Prok AL; Prayson RA
    Ann Diagn Pathol; 2006 Apr; 10(2):67-71. PubMed ID: 16546039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.
    Terry J; Leung S; Laskin J; Leslie KO; Gown AM; Ionescu DN
    Am J Surg Pathol; 2010 Dec; 34(12):1805-11. PubMed ID: 21107086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
    El Hag M; Schmidt L; Roh M; Michael CW
    Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues.
    Nakamura N; Miyagi E; Murata S; Kawaoi A; Katoh R
    Mod Pathol; 2002 Oct; 15(10):1058-67. PubMed ID: 12379752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
    Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
    Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.
    Agoff SN; Lamps LW; Philip AT; Amin MB; Schmidt RA; True LD; Folpe AL
    Mod Pathol; 2000 Mar; 13(3):238-42. PubMed ID: 10757334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.
    Kadivar M; Boozari B
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):191-5. PubMed ID: 22914608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma.
    Roh MH; Schmidt L; Placido J; Farmen S; Fields KL; Courey AJ; Arenberg DA; Knoepp SM
    Diagn Cytopathol; 2012 Nov; 40(11):949-55. PubMed ID: 21500373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
    Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.
    Kadota K; Nitadori J; Rekhtman N; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2015 Sep; 39(9):1170-80. PubMed ID: 25871623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.
    Wu J; Zhang Y; Ding T; Cheng R; Gong W; Guo Y; Luo Y; Pan Y; Zhai Q; Sun W; Lin D; Sun B
    Endocr Pathol; 2020 Mar; 31(1):39-45. PubMed ID: 31788765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.
    Ueno T; Linder S; Elmberger G
    Br J Cancer; 2003 Apr; 88(8):1229-33. PubMed ID: 12698189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes.
    Roh MS; Hong SH
    J Korean Med Sci; 2002 Aug; 17(4):512-7. PubMed ID: 12172048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
    Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
    Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Thyroid transcription factor-1 in pulmonary cytology].
    Smojver-Jezek S; Vrabec-Branica B; Juros Z; Boras Z; Cucević B; Mazuranić I
    Acta Med Croatica; 2008 Oct; 62(4):373-8. PubMed ID: 19205414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
    Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
    Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.